Unlike conventional products, Inventage Lab’s two formulations of long-acting injections for prostate cancer have demonstrated groundbreaking control over initial overrelease (0.14-7.65...
Studies exploring metformin’s power to prevent prostate cancer progression have been inconclusive. Columbia research now shows that the drug has promise, but only for specific patients.
JW Pharmaceutical said a lead compound for prostate cancer refractory or resistant to standard therapies, developed by its subsidiary C&C Research Laboratories, has been selected for national drug...
The following is a list of cancer drugs approved by the Food and Drug Administration (FDA) specifically for the treatment of prostate cancer. The list includes both generic names and brand names, w...
Medications for prostate cancer include hormone therapy such as leuprolide (Lupron Depot, Eligard), leuprolide mesylate (Camcevi), goserelin (Zoladex), and
What is prostate-specific membrane antigen PET? (PSMA PET Scan) ; New imaging technique for prostate cancer that locates cancer lesions. ; PSMA PET uses a PET-sensitive drug (68Ga-PSMA-11) that is FDA approved. ; 68Ga-PSMA-11 is a radioactive imaging agent that binds to prostate cancer cells to help localize prostate cancer cells.
Prostate cancer (PCa) carries a growing burden on society. Lack of curative treatment and poor prognosis among patients with advanced PCa imply an urgent need for novel and improved drug identifica...
Photo: Arnd Wiegmann/REUTERS A drug used to extend the lives of people with advanced prostate cancer is in short supply and will be for months, leaving some patients with no treatment...
Prostate cancer drug Xtandi (enzalutamide), in combination with androgen deprivation therapy (ADT) to treat patients with metastatic hormone-sensitive prostate cancer (mHSPC), will see its reimbursement status change from selective to essential starting next month. After winning approval for treating metastatic castration-resistant prostate cancer (mCRPC) in 2013, Xtandi was also approved to treat high-risk, non-metastatic castration-resistant prostate cancer. In September 2021, an indication was added to treat all patients with mHSPC, allowing ...
Novartis' radioligand therapy Pluvicto (lutetium vipivotide tetraxetan) is drawing attention by receiving approval in Korea. The Ministry of Food and Drug Safety (MFDS) said Wednesday that it has approved Pluvicto, an orphan drug for prostate cancer imported by Novartis Korea. Pluvicto is a radiotherapy drug that delivers therapeutic radiation to prostate cancer cells by binding the radioactive isotope lutetium (177Lu) to prostate-specific membrane antigen (PSMA), which is highly expressed in prostate cancer, killing the cancer cells. ...